Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Medicure (MCUJF) EBITDA Margin (2016 - 2025)

Medicure has reported EBITDA Margin over the past 17 years, most recently at 51.9% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 6449.0% year-over-year to 51.9%; the TTM value through Dec 2025 reached 22.92%, down 2603.0%, while the annual FY2025 figure was 27.74%, 3087.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 51.9% at Medicure, down from 12.67% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 44.83% in Q3 2022 and troughed at 51.9% in Q4 2025.
  • A 5-year average of 3.23% and a median of 2.74% in 2022 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 23381bps in 2021 and later plummeted -6449bps in 2025.
  • Year by year, EBITDA Margin stood at 20.76% in 2021, then tumbled by -96bps to 0.78% in 2022, then crashed by -4276bps to 32.4% in 2023, then soared by 139bps to 12.59% in 2024, then tumbled by -512bps to 51.9% in 2025.
  • Business Quant data shows EBITDA Margin for MCUJF at 51.9% in Q4 2025, 12.67% in Q3 2025, and 27.26% in Q2 2025.